International Journal of Research in Engineering and Management Sciences (IJREMS)
E-ISSN: 3107-7439

Research Article
VOL.: 1, Issue: 7, December 2025

Digital Twin Technology: The Next Frontier in Personalized Oncology

***[1]Dr. Rajeev Malhotra, [2]Dr. Pooja Bansal, [3]Dr. Deepika Verma**

*[*1]Professor Department of Radiology, King George's Medical University, Lucknow, India*
Rajeevmalhotra84@gmail.com
[2]Assistant Professor Department of Pharmacology, King George's Medical University, Lucknow, India
Pooja.bansal311@gmail.com
[3] Associate Professor Department of Pathology, King George's Medical University, Lucknow, India
Deepika.verma66@gmail.com

ABSTRACT:

Cancer remains one of the most complex diseases confronting modern medicine because of its remarkable biological heterogeneity, dynamic evolution, and highly individualized therapeutic responses. Despite substantial advances in molecular diagnostics, targeted therapies, immunotherapy, and precision medicine, considerable variability in clinical outcomes continues to challenge conventional treatment strategies. Recent developments in artificial intelligence (AI), computational biology, systems medicine, mathematical modeling, and multimodal biomedical data integration have introduced digital twin technology as one of the most promising innovations in personalized oncology. A digital twin is a continuously evolving virtual representation of an individual patient that integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, physiological monitoring, treatment history, and longitudinal clinical data to simulate disease progression and therapeutic response. Unlike traditional predictive models that analyze isolated datasets, digital twins provide dynamic, patient-specific computational ecosystems capable of supporting diagnosis, prognostic prediction, treatment optimization, toxicity assessment, adaptive therapy, and survivorship planning. Advances in machine learning, deep learning, transformer architectures, graph neural networks, reinforcement learning, generative AI, and foundation models have significantly accelerated the development of oncology digital twins by enabling continuous integration of heterogeneous biomedical information. These intelligent systems have demonstrated growing potential across tumor detection, radiogenomics, computational pathology, immunotherapy prediction, adaptive radiation therapy, surgical planning, drug discovery, and clinical decision support. Nevertheless, challenges remain regarding data harmonization, interoperability, computational complexity, cybersecurity, explainability, ethical governance, regulatory validation, and widespread clinical implementation. This review provides a comprehensive overview of digital twin technology in oncology, emphasizing its computational foundations, current clinical applications, emerging innovations, and future role in transforming personalized cancer care.[1]

Keywords: Digital twins, Artificial intelligence, Precision oncology, Personalized medicine, Computational oncology, Digital pathology, Radiogenomics, Clinical decision support, Machine learning, Systems biology.

Received Date: 5 December 2025**; Accepted Date:** 15 December 2025**; Published Date:** 20 December 2025.

Introduction

Cancer is a multifactorial disease driven by complex interactions among genetic mutations, epigenetic alterations, transcriptional regulation, metabolic reprogramming, immune dysregulation, and the continuously evolving tumor microenvironment. Although advances in molecular oncology and precision medicine have substantially improved survival across many malignancies, patients with apparently similar histopathological diagnoses frequently demonstrate markedly different therapeutic responses, recurrence patterns, and long-term outcomes. This biological heterogeneity highlights the limitations of conventional population-based treatment strategies and underscores the need for truly individualized approaches to cancer management.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable sensors, and electronic health records. While these diverse datasets collectively provide an increasingly comprehensive understanding of tumor biology, their complexity often exceeds the analytical capabilities of conventional statistical methods and routine clinical workflows. Integrating these multidimensional data into meaningful clinical decisions remains one of the greatest challenges in precision oncology.[3]

Artificial intelligence has emerged as a transformative technology capable of extracting clinically relevant knowledge from complex biomedical datasets. Machine learning and deep learning algorithms have demonstrated remarkable success in cancer diagnosis, prognostic prediction, molecular characterization, treatment response estimation, and clinical decision support. More recently, advances in computational modeling have expanded beyond isolated predictive algorithms toward dynamic virtual representations of individual patients, giving rise to the concept of digital twins.[4]

Digital twin technology represents a paradigm shift in personalized oncology by enabling clinicians to create continuously updated virtual models that evolve alongside biological patients. These computational models integrate multimodal biomedical information and simulate disease progression, therapeutic interventions, and clinical outcomes, allowing physicians to evaluate multiple treatment scenarios before implementing them in real-world clinical practice.[5]

2. Evolution of Digital Twin Technology in Healthcare

The concept of digital twins originated in engineering and industrial manufacturing, where virtual replicas of physical systems were developed to optimize operational performance, predict equipment failures, and improve maintenance strategies. Aerospace organizations pioneered digital twin applications by creating computational models capable of continuously monitoring aircraft performance under varying operational conditions. Similar approaches were subsequently adopted across automotive engineering, robotics, energy systems, and smart manufacturing.[6]

Healthcare researchers later recognized that these engineering principles could be adapted to biological systems. Instead of representing mechanical components, healthcare digital twins model physiological processes, disease progression, therapeutic interventions, and patient-specific biological responses. Early medical applications focused on cardiovascular disease, diabetes, orthopedics, intensive care medicine, and physiological monitoring, where continuous clinical measurements could be integrated into predictive computational models.[7]

Rapid advances in biomedical technologies—including next-generation sequencing, high-resolution medical imaging, wearable biosensors, molecular diagnostics, and cloud-based electronic health records—have accelerated the evolution of healthcare digital twins. Artificial intelligence has become indispensable for processing these large-scale datasets and transforming them into clinically actionable predictions.

Oncology has emerged as one of the most promising fields for digital twin implementation because cancer requires continuous integration of imaging, molecular biology, pathology, genomics, immunology, and longitudinal clinical information. The highly individualized nature of tumor biology makes digital twin technology particularly well suited for precision cancer care.[8]

3. Computational Architecture of Oncology Digital Twins

An oncology digital twin is not a single artificial intelligence model but rather a sophisticated computational ecosystem composed of multiple interconnected components that continuously exchange information to represent the evolving biological state of an individual patient.[9]

The first computational layer involves acquisition of multimodal biomedical information from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable monitoring devices, treatment records, medication histories, and electronic health records. Each data source contributes complementary information regarding tumor biology and patient health status.

The second layer performs data harmonization and preprocessing. Because biomedical information originates from diverse technologies using different formats, advanced computational pipelines normalize imaging data, standardize molecular profiles, encode clinical narratives through natural language processing, and integrate heterogeneous datasets into unified computational representations.

The third layer consists of advanced artificial intelligence algorithms responsible for predictive modeling. Deep neural networks analyze medical images, transformer architectures interpret clinical narratives, graph neural networks model molecular interaction networks, and probabilistic learning algorithms estimate disease progression and therapeutic response.

Simulation engines subsequently integrate these computational outputs into mathematical models capable of predicting tumor growth, metastatic dissemination, immune interactions, treatment efficacy, toxicity profiles, and resistance mechanisms. Continuous incorporation of newly acquired patient information enables the digital twin to evolve dynamically alongside the biological patient.[10]

4. Artificial Intelligence as the Foundation of Digital Twins

Artificial intelligence forms the computational backbone of modern oncology digital twins by enabling continuous learning from complex biomedical information. Multiple complementary AI techniques operate simultaneously to transform raw clinical data into clinically actionable predictions.[11]

Machine learning algorithms identify statistical relationships between patient characteristics and clinical outcomes, supporting prediction of recurrence, survival, and treatment response. Deep learning further enhances these capabilities through automated feature extraction from radiological images, histopathological slides, genomic datasets, and physiological signals.

Transformer architectures have become increasingly important because they efficiently process heterogeneous multimodal datasets while preserving long-range contextual relationships across imaging, molecular biology, pathology, laboratory investigations, and clinical documentation. Graph neural networks provide additional capabilities by modeling biological interaction networks involving genes, proteins, signaling pathways, and cellular communication.

Foundation models trained on large biomedical datasets further improve scalability by learning generalized clinical representations that can be adapted across numerous oncology applications through transfer learning, reducing dependence on manually annotated datasets while improving generalizability across different cancer types and healthcare systems.[12]

5. Multimodal Data Integration

The effectiveness of oncology digital twins depends upon seamless integration of diverse biomedical information into unified computational frameworks. Cancer biology cannot be adequately represented using any single data modality because tumor behavior reflects interactions among genetic, molecular, cellular, physiological, anatomical, environmental, and clinical factors.[13]

Radiological imaging contributes anatomical and functional information regarding tumor morphology, vascularity, metabolic activity, and disease progression. Digital pathology provides microscopic characterization of tissue architecture, cellular differentiation, stromal remodeling, angiogenesis, immune infiltration, and tumor heterogeneity.

Genomic sequencing identifies driver mutations and inherited susceptibility variants, whereas transcriptomics reflects dynamic gene expression patterns. Proteomics, metabolomics, immunomics, and laboratory biomarkers provide additional insight into cellular function, therapeutic response, and disease evolution.

Artificial intelligence enables harmonization of these heterogeneous datasets through multimodal representation learning, generating comprehensive patient-specific computational models that continuously evolve as new clinical information becomes available.[14]

6. Digital Twins in Diagnostic Imaging

Medical imaging serves as one of the principal pillars of oncology digital twins because radiological examinations provide continuous, non-invasive assessment of tumor characteristics throughout diagnosis, treatment, and follow-up. Computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and hybrid imaging contribute essential anatomical and functional information to virtual patient models.[15]

Deep learning algorithms automatically detect tumors, segment lesions, quantify tumor burden, characterize imaging phenotypes, and monitor longitudinal changes during treatment. Radiomics further expands these capabilities by extracting quantitative imaging biomarkers that describe tumor heterogeneity, texture, morphology, vascularity, and spatial organization.

Longitudinal imaging analysis enables digital twins to update continuously following surgery, chemotherapy, targeted therapy, immunotherapy, or radiation treatment. These adaptive models facilitate early recognition of treatment response or disease progression, enabling clinicians to modify therapeutic strategies before clinically significant deterioration occurs.[16]

7. Digital Pathology and Computational Histopathology

Digital pathology has become another essential component of oncology digital twins. Whole-slide imaging technologies generate ultra-high-resolution digital tissue images that allow artificial intelligence systems to analyze millions of microscopic regions simultaneously.[17]

Deep learning and transformer-based computational pathology models identify subtle histomorphological features associated with tumor subtype, cellular differentiation, stromal architecture, angiogenesis, necrosis, immune infiltration, and metastatic potential. These microscopic biomarkers significantly enhance diagnostic accuracy and prognostic prediction.

Recent advances have demonstrated that AI can infer clinically important molecular alterations—including EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression—directly from routine histopathological images. Integration of these computational pathology outputs into oncology digital twins further strengthens personalized treatment planning while reducing dependence on additional molecular testing in selected clinical settings.[18]

8. Radiogenomics and Molecular Imaging

Radiogenomics has emerged as one of the most important translational applications of oncology digital twins by establishing relationships between radiological imaging features and underlying genomic and molecular characteristics. This interdisciplinary field combines artificial intelligence, quantitative imaging, and molecular biology to identify imaging biomarkers capable of predicting clinically significant genetic alterations without requiring repeated tissue biopsies.[19]

Machine learning and deep learning algorithms analyze radiomic features together with genomic sequencing, transcriptomic profiles, and molecular biomarkers to identify associations between tumor morphology and biological pathways. These computational models enable prediction of driver mutations, molecular subtypes, treatment sensitivity, and disease aggressiveness using routinely acquired medical imaging.

Within digital twin ecosystems, radiogenomics enables continuous molecular assessment throughout disease progression by updating virtual patient models with new imaging information. This capability is particularly valuable for metastatic disease, where repeated tissue sampling may be technically difficult or clinically unsafe. Integration of radiological and molecular information provides a dynamic representation of tumor evolution that supports adaptive treatment planning and precision oncology.

9. Digital Twins in Immuno-Oncology

Immunotherapy has revolutionized cancer treatment by harnessing the patient's immune system to recognize and eliminate malignant cells. However, predicting which patients will benefit from immune checkpoint inhibitors and other immunotherapeutic approaches remains a major challenge because of the complexity of immune-tumor interactions.

Digital twins address this challenge by integrating genomic alterations, immunomic profiles, cytokine signaling pathways, tumor mutational burden, digital pathology, radiological imaging, circulating biomarkers, and clinical information into comprehensive computational models.[20]

Artificial intelligence characterizes tumor-infiltrating lymphocytes, immune checkpoint expression, stromal barriers, inflammatory pathways, and immune-cell spatial organization. These data enable simulation of immune responses under different therapeutic strategies, providing individualized estimates of treatment efficacy and toxicity.

Future digital twins are expected to support optimization of immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies through continuous refinement of patient-specific immune models.

10. Personalized Treatment Planning

Perhaps the greatest clinical advantage of oncology digital twins lies in individualized treatment optimization. Rather than relying solely on standardized treatment protocols derived from population-level clinical trials, clinicians can evaluate multiple therapeutic scenarios within a patient's virtual model before initiating therapy.[21]

Simulation engines estimate tumor response, treatment toxicity, recurrence probability, progression-free survival, and overall survival under different therapeutic strategies. Virtual experimentation enables comparison of chemotherapy regimens, targeted therapies, immunotherapy combinations, surgical interventions, and radiation treatment plans while minimizing unnecessary patient risk.

Because digital twins continuously incorporate updated clinical information, therapeutic recommendations evolve throughout the patient's disease course. This adaptive approach recognizes that cancer biology changes over time and therefore requires flexible rather than static treatment strategies.

11. Adaptive Radiation Oncology

Radiation therapy remains one of the principal modalities for cancer treatment; however, tumor size, anatomical position, and surrounding normal tissues often change throughout the treatment course. Conventional radiation plans may therefore become suboptimal as therapy progresses.

Digital twins overcome these limitations by continuously incorporating sequential imaging acquired during radiation therapy. Artificial intelligence automatically updates tumor contours, predicts anatomical changes, estimates radiation sensitivity, and recommends individualized treatment modifications.[22]

Adaptive radiation planning enables clinicians to optimize dose distribution according to evolving patient anatomy while minimizing unnecessary radiation exposure to surrounding healthy tissues. These computational simulations improve tumor control, reduce treatment-related toxicity, and enhance precision radiation oncology.

12. Surgical Planning and Intraoperative Guidance

Digital twin technology is increasingly being investigated for surgical oncology applications. Three-dimensional patient-specific virtual models generated from radiological imaging provide detailed visualization of tumor location, vascular anatomy, adjacent organs, and critical neurovascular structures before surgery.[23]

Artificial intelligence enhances surgical planning by predicting optimal resection margins, estimating operative complexity, assessing postoperative complications, and simulating multiple operative approaches before the procedure. These virtual simulations improve preoperative planning while supporting personalized surgical decision-making.

Future integration of robotic surgery, intraoperative imaging, navigation systems, and real-time physiological monitoring may allow digital twins to update dynamically during surgical procedures, providing continuous guidance that improves surgical precision and patient safety.

13. Digital Twins in Drug Discovery and Clinical Trials

Development of new anticancer therapies remains expensive, time-consuming, and associated with high failure rates. Digital twins offer innovative opportunities for accelerating drug discovery by enabling computational simulation of therapeutic responses before laboratory or clinical testing.[24]

Artificial intelligence integrates molecular biology, pharmacology, genomics, proteomics, and patient-specific disease models to predict drug efficacy, toxicity, resistance mechanisms, and optimal dosing strategies. These virtual experiments may substantially reduce development costs while improving clinical success rates.

Digital twins also have important implications for clinical trial design. Computational patient models can identify individuals most likely to benefit from experimental therapies, improve patient stratification, reduce trial variability, and potentially support the development of validated virtual control groups that complement conventional clinical trial methodologies.

14. Clinical Decision Support and Future Clinical Integration

Modern oncology requires interpretation of enormous quantities of clinical information generated throughout diagnosis, treatment, and follow-up. Digital twins function as intelligent clinical decision-support systems by continuously integrating laboratory investigations, radiological imaging, pathology reports, genomic sequencing, treatment responses, and longitudinal clinical outcomes into comprehensive patient-specific computational models.[25]

Interactive dashboards provide clinicians with individualized predictions regarding disease progression, treatment efficacy, toxicity risk, recurrence probability, and survival outcomes. Rather than replacing physician expertise, these systems provide evidence-based computational insights that facilitate multidisciplinary decision-making and personalized patient management.

As healthcare increasingly adopts electronic health records, wearable biosensors, remote monitoring technologies, cloud computing, and real-time data integration, digital twins are expected to become central components of future precision oncology ecosystems capable of supporting continuous learning and adaptive clinical care.

15. Explainable Artificial Intelligence, Ethics, and Future Directions

For oncology digital twins to achieve widespread clinical adoption, their predictions must be transparent, interpretable, and trustworthy. Explainable artificial intelligence (XAI) has therefore become an essential component of digital twin development. Techniques including attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution, and counterfactual explanations enable clinicians to understand the biological factors influencing AI-generated predictions.[26]

Important ethical and regulatory considerations include patient privacy, informed consent, algorithmic bias, cybersecurity, data ownership, interoperability, and clinical accountability. Large-scale deployment will require standardized data models, rigorous prospective validation, international regulatory frameworks, and secure computational infrastructure.

Emerging technologies—including foundation models, federated learning, quantum computing, spatial multi-omics, wearable biosensors, and generative AI—are expected to substantially enhance the scalability and predictive capabilities of oncology digital twins. These innovations may eventually enable continuously learning virtual patients capable of supporting every stage of cancer management, from early detection through survivorship.

16. Discussion

Digital twin technology represents one of the most significant advances in artificial intelligence-driven precision oncology. By integrating radiology, pathology, genomics, molecular biology, laboratory biomarkers, physiological monitoring, and longitudinal clinical information into continuously evolving virtual patient models, digital twins provide an unprecedented framework for personalized cancer care.[27]

Applications across diagnostic imaging, computational pathology, radiogenomics, immunotherapy, adaptive radiation therapy, surgical planning, drug discovery, and clinical decision support demonstrate the broad translational potential of this technology. Unlike conventional predictive algorithms that rely on isolated datasets, digital twins continuously adapt to new patient information, allowing individualized simulation of disease progression and therapeutic response.

Nevertheless, widespread implementation depends upon overcoming substantial challenges related to data standardization, computational complexity, explainability, interoperability, cybersecurity, regulatory approval, and equitable clinical access. Addressing these barriers will require close collaboration among oncologists, computer scientists, biomedical engineers, molecular biologists, regulatory agencies, and healthcare organizations.[28]

17. Conclusion

Digital twin technology is redefining the future of personalized oncology by creating continuously evolving computational representations of individual patients capable of integrating multimodal biomedical information into clinically actionable insights. Their ability to combine radiological imaging, digital pathology, genomics, transcriptomics, laboratory biomarkers, wearable technologies, and longitudinal clinical records enables personalized diagnosis, prognostic prediction, adaptive treatment planning, toxicity assessment, and long-term survivorship management.[29]

As artificial intelligence, multimodal learning, foundation models, federated learning, and computational biology continue to advance, oncology digital twins are expected to become increasingly accurate, scalable, and clinically applicable. Although important scientific, technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research is steadily moving digital twins toward routine clinical implementation.

By enabling individualized simulation of disease evolution and therapeutic response before clinical intervention, digital twins have the potential to transform oncology from a predominantly reactive discipline into a predictive, preventive, adaptive, and truly personalized model of cancer care, ultimately improving clinical outcomes and advancing the future of precision medicine.[30]

References

1. Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.
3. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.
4. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.
5. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.
6. Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.
7. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.
8. Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
9. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.
10. Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.
11. Boehm, K.M. et al. (2022) ‘Harnessing Multimodal Data Integration to Advance Precision Oncology’, Nature Reviews Cancer, 22(2), pp. 114–126.
12. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
13. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
14. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
15. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
16. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
17. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
18. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
19. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING

THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

20. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
21. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
22. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
23. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14
24. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
25. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
26. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
27. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
28. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
29. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
30. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8